CD8A and Miyoshi myopathy: In 2023, the FDA also approved talquetamab, a highly selective humanized bispecific mAb that binds to the GPRC5D receptor and CD3 receptors expressed on the surface of MM cells, inducing T-cell activation and degranulation of CD4+ and CD8+ T-cells, leading to the death of MM cells [137].